On March 26, 2024, Moderna Inc. Headquarters in Cambridge, Massachusetts.
Adam Glanzman | Bloomberg | Getty Images
Modern Say its experiment on Monday mRNA-based influenza vaccine The immune response was produced stronger than the lenses currently obtained in later trials, clearing the product’s path forward and the company’s separate combination of Flu and Covid Jab.
May’s modern Voluntary withdrawal of the application Seeking approval of its combined shooting against Covid-19 and influenza, saying it plans to resubmit through efficacy data from its Phase 3 trial in its standalone influenza vaccine. The decision comes after discussions with the Food and Drug Administration, which is in the process of health and human services secretary Robert F. Kennedy Jr.
Stephen Hoge, the company’s head of research and development, said in an interview that with the help of new data, the company plans to resubmit a joint vaccine application and apply for independent flu vaccine approval later this year.
Hoge said the company could advance the merger lens if regulators approve the flu vaccine. He added that Moderna hopes to approve both shots next year, awaiting comments.
Moderna shares climbed more than 5% in listing trading on Monday.
Hogg said the jab combination simplifies vaccination, which will “help the healthcare system” by reducing the workload of doctors and nurses, cutting costs and improving patient intake.
So far, the company seems to be with Pfizer and Novavax Bring combinations to the market. Although ModernA has no specific revenue forecast for its individual products, Hoge says Covid, Flu and respiratory synthesis viruses are all multi-billion dollar markets.
“We obviously want our products to win their receivable share,” he said.
The third phase trial conducted more than 40,000 adults aged 50 and older who were randomly assigned to a single dose of Moderna shot, called MRNA-1010 or standard competitor vaccine. Moderna shot 26.6% higher than other vaccines throughout the study population.
mRNA-1010 bayonet also showed strong efficacy on each major influenza strain in the camera, including the A/H1N1, A/H3N2 and B/Victoria lineages. Moderna said the benefits of the vaccine are consistent among people of different age groups, with various risk factors and those with previously vaccinated status against influenza.
Among adults aged 65 and over, shooting is 27.4% higher than the standard flu vaccine.
“Efficacy results are an important milestone in reducing the burden on flu in older people,” Hyundai CEO Stephane Bancel said in a press release. “The severity of past flu seasons highlighted the need for more effective vaccines.”
Modern Quotes data The Centers of the Centers for Disease Control and Prevention show that during the viral season between 2024 and 2025, seasonal flu-related inpatient and outpatient visits reached 15 years. More than 600,000 Americans The CDC said it was hospitalized last year for flu-related illnesses.
Safety data for the MRNA-1010 vaccine are consistent with previous results from another phase 3 study taken.
Hyundai stocks, which entered a year on Monday, fell more than 30%, largely by a series of actions taken by the Trump administration to change vaccine policies and undermine immunizations. The government in May Cancel The contract awarded to Moderna, which was awarded to humans for the later development of its bird flu vaccine.
Asked about the uncertain regulatory environment in the United States, Hoge said Moderna is in close contact with the FDA to understand what its requirements are and how they can be met.
“I believe it’s about the flu, and I think we have a very clear path,” he said.
